These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17502864)

  • 1. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.
    Wallis RS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):16-21. PubMed ID: 17502864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.
    Saliu OY; Sofer C; Stein DS; Schwander SK; Wallis RS
    J Infect Dis; 2006 Aug; 194(4):486-92. PubMed ID: 16845632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
    Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
    Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.
    Harris J; Hope JC; Keane J
    J Infect Dis; 2008 Dec; 198(12):1842-50. PubMed ID: 18954258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of TNF antagonists on the T-lymphocyte response.
    Emilie D
    Joint Bone Spine; 2007 Dec; 74(6):558-9. PubMed ID: 17950650
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycobacterium tuberculosis-induced cell death of primary human monocytes and macrophages is not significantly modulated by tumor necrosis factor-targeted biologicals.
    Reiling N; Schneider D; Ehlers S
    J Investig Dermatol Symp Proc; 2007 May; 12(1):26-33. PubMed ID: 17502866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor blockade: mechanism of action.
    Gottlieb AB
    J Investig Dermatol Symp Proc; 2007 May; 12(1):1-4. PubMed ID: 17502861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.
    Fallahi-Sichani M; Flynn JL; Linderman JJ; Kirschner DE
    J Immunol; 2012 Apr; 188(7):3169-78. PubMed ID: 22379032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
    Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept.
    Shen C; Assche GV; Colpaert S; Maerten P; Geboes K; Rutgeerts P; Ceuppens JL
    Aliment Pharmacol Ther; 2005 Feb; 21(3):251-8. PubMed ID: 15691299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
    Wallis RS
    Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of latent granulomatous infections by infliximab.
    Wallis RS; Broder M; Wong J; Lee A; Hoq L
    Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.